A Long-Term Multicenter, Randomized, Double-Blind, Controlled, Parallel Group Study of the Safety and Efficacy of Lemborexant in Subjects With Insomnia Disorder
Phase of Trial: Phase III
Latest Information Update: 17 Aug 2017
At a glance
- Drugs Lemborexant (Primary)
- Indications Insomnia
- Focus Registrational; Therapeutic Use
- Sponsors Eisai Co Ltd
- 08 Aug 2017 Planned End Date changed from 1 Dec 2018 to 1 Jan 2019.
- 08 Aug 2017 Planned primary completion date changed from 1 Nov 2018 to 1 Dec 2018.
- 06 Dec 2016 Status changed from not yet recruiting to recruiting.